Acacia Pharma Raises $23.5 M Series B For Repurposing Drugs As Anti-Emetics
This article was originally published in The Pink Sheet Daily
Other product candidates in the cancer supportive care sector being developed by the U.K. virtual biotech include a liquid formulation of a muscarinic agonist for dry mouth and a megestrol/formoterol combination therapy for muscle wasting.
You may also be interested in...
The EU's CHMP gave positive opinions on three new products – Novartis' glycopyrronium, AstraZeneca's ceftaroline and Takeda's teduglutide – and on a major new indication for Novartis’ everolimus (Afinitor), after its meeting on June 18-21.
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.